ArticleACR open rheumatology2021

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.

Joel M Kremer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.